| Biomarker ID | 1365 |
| PMID | 24682418 |
| Year | 2014 |
| Biomarker | CYP1B1: [SNP: rs1800440: A>G] |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | Blood |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 2.58 (95% CI: 1.47–4.52) |
| Effect on Pathways | Pathways include: Tamoxifen metabolism, Estrogen metabolism, Cytochrome P450 metabolism of endogenous sterols, Phase I of biological oxidations: functionalization of compounds, Cytochrome P450 pathway |
| Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | Cohort of 213 men with advanced prostate cancer were chosen for analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.0009 |
| Method Used | MALDI-TOF |
| Clinical | No |
| Remarks | Cox regression models included PSA at diagnosis, Gleason score, pathologic T stage, age at diagnosis, neoadjuvant hormone therapy, smoking status, adjuvant therapy, surgical margin, and nodal invasion status. The major-allele homozygotes served as the reference group with a fixed HR of 1.00. |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |